[Case Study] Akari Shigemi “The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance” (AMR Alliance Japan, December 22, 2021)
date : 12/22/2021
Tags: AMR
As part of the Alliance’s project to promote antimicrobial steward among medical professionals, AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) has begun publishing case studies from various experts related to antimicrobial resistance.
Akari Shigemi (Division of Pharmacy / Department of Infection Control and Prevention, Kagoshima University Hospital) reports a case titled “The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance”.
Case study 04
Dr. Akari Shigemi (Division of Pharmacy / Department of Infection Control and Prevention, Kagoshima University Hospital)
“The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance”
For further information, please see the case study below.
Case study 01
Dr. Keiji Okinaka (Director of Infection Control and Prevention Section, National Cancer Center Hospital East / Department of General Internal Medicine, National Cancer Center Hospital East /Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital)
“A disseminated filamentous fungal infection that broke through echinocandin antifungal treatment”
Top Research & Recommendations Posts
Featured Posts
-
2026-08-28
[Announcement] The 3rd Kiyoshi Kurokawa Award: Call for Nominations (Deadline: November 30, 2026)
-
2026-10-06
[Registration Open] (Webinar) The 146th HGPI Seminar “How We Can Build a Society That Supports Choices Around Organ Donation: Exploring Decision-Making by Citizens and a Multi-Layered Approach Through Strategic Social Marketing” (November 9, 2026)
-
2026-10-19
[HGPI Policy Column] (No.78) — From the Blood Disorders Project “Quality of Life in Long-Term Blood Cancer Care: Insights from Canada”
-
2026-10-28
[Policy Recommendations] Driving Progress in Intractable and Rare Disease Policy Through Patient and Public Voices: Towards Redesigning Healthcare Delivery Systems Across Diagnosis (September 29, 2026)



